FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895042937> ?p ?o ?g. }

• W2895042937 endingPage "1930" @default.
• W2895042937 startingPage "1922" @default.
• W2895042937 abstract "Recent safety concerns regarding gadolinium-based contrast agents (GdCAs) concluded with the suspension of some agents from the European market, yet a clinical consequence remains unknown. We used electronic health records to investigate the incidence of potential toxicity to gadoteric acid (Dotarem®) within our local population, including those with renal insufficiency (RI). Data for patients who underwent contrast-enhanced MRI were identified, stratified by renal function at time of scan and retrospectively followed using routinely collected health data. Searches performed were: records of hypersensitivity reactions; diagnoses of nephrogenic systemic fibrosis (NSF); onset of chronic pain, a symptom that has been associated with NSF and the theorised gadolinium deposition disease (GDD); and post-contrast acute kidney injury (PC-AKI). Comparisons were made between patients and controls (those who underwent non-contrast scans) via chi-square and ANOVA statistical tests. Of the 22,897 contrast-enhanced MRI scans performed locally from 2004–2016 (adult, n = 22,325 and paediatric, n = 572), 14% were performed on patients with RI (30 ≤ eGFR < 60, n = 2,622; 15 ≤ eGFR < 30, n = 464; eGFR < 15, n = 123). Two adult patients (0.01%) suffered hypersensitivity reactions. Zero cases of NSF were reported, with an average follow-up time of 6.0 ± 2.5 years (range, 8 months–15 years). Analysis failed to highlight statistically higher rates of chronic pain onset post-MRI (adult: p = 0.777, paediatric: p = 0.578), or PC-AKI (adult: p = 0.566, paediatric: p = 0.841), in the patient groups compared to controls. These data indicate that administration of gadoteric acid to RI patients does not result in a higher rate of signs or symptoms that may be associated with gadolinium toxicity when compared to controls. • Following 22,897 administrations of gadoteric acid to a local population, there was no association with symptoms that may be associated with gadolinium toxicity. • Zero cases of nephrogenic systemic fibrosis were reported following 3,209 gadoteric acid administrations to a cohort of renally insufficient patients. • A low number of hypersensitivity reactions were observed (0.01%) and no higher rate of chronic pain or post-contrast acute kidney injury were noted when compared with a control cohort of non-contrast-enhanced examinations." @default.
• W2895042937 created "2018-10-12" @default.
• W2895042937 creator A5014772013 @default.
• W2895042937 creator A5042508466 @default.
• W2895042937 creator A5068989165 @default.
• W2895042937 date "2018-10-01" @default.
• W2895042937 modified "2023-09-26" @default.
• W2895042937 title "Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals" @default.
• W2895042937 cites W1742887464 @default.
• W2895042937 cites W1972315262 @default.
• W2895042937 cites W2002676493 @default.
• W2895042937 cites W2020777065 @default.
• W2895042937 cites W2023614620 @default.
• W2895042937 cites W2041800883 @default.
• W2895042937 cites W2061514693 @default.
• W2895042937 cites W2061948232 @default.
• W2895042937 cites W2067516124 @default.
• W2895042937 cites W2094548421 @default.
• W2895042937 cites W2094995342 @default.
• W2895042937 cites W2097958959 @default.
• W2895042937 cites W2101574919 @default.
• W2895042937 cites W2106072083 @default.
• W2895042937 cites W2117804723 @default.
• W2895042937 cites W2123332553 @default.
• W2895042937 cites W2150437371 @default.
• W2895042937 cites W2150489367 @default.
• W2895042937 cites W2155961553 @default.
• W2895042937 cites W2157433411 @default.
• W2895042937 cites W2169262628 @default.
• W2895042937 cites W2312938814 @default.
• W2895042937 cites W2343520020 @default.
• W2895042937 cites W2353345075 @default.
• W2895042937 cites W2400913366 @default.
• W2895042937 cites W2407825305 @default.
• W2895042937 cites W2412628897 @default.
• W2895042937 cites W2460505725 @default.
• W2895042937 cites W2485693178 @default.
• W2895042937 cites W2507120718 @default.
• W2895042937 cites W2525366881 @default.
• W2895042937 cites W2530579496 @default.
• W2895042937 cites W2558476943 @default.
• W2895042937 cites W2582537586 @default.
• W2895042937 cites W2734479203 @default.
• W2895042937 cites W2759998018 @default.
• W2895042937 cites W2791689004 @default.
• W2895042937 cites W4247811478 @default.
• W2895042937 doi "https://doi.org/10.1007/s00330-018-5737-z" @default.
• W2895042937 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6420614" @default.
• W2895042937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30276674" @default.
• W2895042937 hasPublicationYear "2018" @default.
• W2895042937 type Work @default.
• W2895042937 sameAs 2895042937 @default.
• W2895042937 citedByCount "26" @default.
• W2895042937 countsByYear W28950429372019 @default.
• W2895042937 countsByYear W28950429372020 @default.
• W2895042937 countsByYear W28950429372021 @default.
• W2895042937 countsByYear W28950429372022 @default.
• W2895042937 countsByYear W28950429372023 @default.
• W2895042937 crossrefType "journal-article" @default.
• W2895042937 hasAuthorship W2895042937A5014772013 @default.
• W2895042937 hasAuthorship W2895042937A5042508466 @default.
• W2895042937 hasAuthorship W2895042937A5068989165 @default.
• W2895042937 hasBestOaLocation W28950429371 @default.
• W2895042937 hasConcept C118552586 @default.
• W2895042937 hasConcept C120665830 @default.
• W2895042937 hasConcept C121332964 @default.
• W2895042937 hasConcept C126322002 @default.
• W2895042937 hasConcept C126838900 @default.
• W2895042937 hasConcept C159641895 @default.
• W2895042937 hasConcept C16568411 @default.
• W2895042937 hasConcept C2778653478 @default.
• W2895042937 hasConcept C2779889316 @default.
• W2895042937 hasConcept C2781027423 @default.
• W2895042937 hasConcept C2908647359 @default.
• W2895042937 hasConcept C29730261 @default.
• W2895042937 hasConcept C513090587 @default.
• W2895042937 hasConcept C61511704 @default.
• W2895042937 hasConcept C71924100 @default.
• W2895042937 hasConcept C99454951 @default.
• W2895042937 hasConceptScore W2895042937C118552586 @default.
• W2895042937 hasConceptScore W2895042937C120665830 @default.
• W2895042937 hasConceptScore W2895042937C121332964 @default.
• W2895042937 hasConceptScore W2895042937C126322002 @default.
• W2895042937 hasConceptScore W2895042937C126838900 @default.
• W2895042937 hasConceptScore W2895042937C159641895 @default.
• W2895042937 hasConceptScore W2895042937C16568411 @default.
• W2895042937 hasConceptScore W2895042937C2778653478 @default.
• W2895042937 hasConceptScore W2895042937C2779889316 @default.
• W2895042937 hasConceptScore W2895042937C2781027423 @default.
• W2895042937 hasConceptScore W2895042937C2908647359 @default.
• W2895042937 hasConceptScore W2895042937C29730261 @default.
• W2895042937 hasConceptScore W2895042937C513090587 @default.
• W2895042937 hasConceptScore W2895042937C61511704 @default.
• W2895042937 hasConceptScore W2895042937C71924100 @default.
• W2895042937 hasConceptScore W2895042937C99454951 @default.
• W2895042937 hasIssue "4" @default.
• W2895042937 hasLocation W28950429371 @default.
• W2895042937 hasLocation W28950429372 @default.

• next